Highlights from October MSC meeting

Purpose
The Member State Committee (MSC) meeting in October 2024 was focused on identifying substances that pose a significant risk to human health and the environment. The committee’s primary objective was to discuss and agree on the identification of triphenyl phosphate as a substance of very high concern (SVHC), due to its endocrine disrupting properties, and to consider alternative testing methods for assessing the bioaccumulation potential of substances in aquatic environments.

Effects on Industry
The identification of triphenyl phosphate as an SVHC will have significant implications for industries that use or manufacture this substance. Companies will be required to undergo a risk assessment and, if necessary, implement measures to mitigate any risks associated with the substance’s endocrine disrupting properties. Additionally, the adoption of the OECD Test Guideline 321 on the Hyalella Azteca test (HYBIT) as the standard information requirement under REACH will likely lead to changes in testing protocols and procedures for industries that use or manufacture substances that require bioaccumulation testing.

Relevant Stakeholders
The stakeholders most affected by this update are companies that use or manufacture triphenyl phosphate, as well as those involved in the development and implementation of alternative testing methods. This includes chemical manufacturers, suppliers, and users, as well as regulatory bodies responsible for enforcing REACH regulations. Consumers may also be indirectly affected through the potential changes to product formulations and labeling.

Next Steps
ECHA will add triphenyl phosphate to the Candidate List in early November 2024, following the MSC’s decision to identify it as an SVHC. Companies that use or manufacture this substance will need to comply with the updated REACH regulations, including conducting risk assessments and implementing measures to mitigate any risks associated with the substance’s endocrine disrupting properties. The MSC will continue its debate on the review of the prioritisation approach for substances to be included in the Authorisation List at its December meeting.

Any Other Relevant Information
The adoption of the OECD Test Guideline 321 on HYBIT test as the standard information requirement under REACH marks another step towards reducing testing on vertebrate animals. This development reflects the ongoing efforts by regulatory bodies and industry stakeholders to develop and implement alternative testing methods that are more humane and efficient. The publication of this guideline provides a clear framework for companies to follow when assessing the bioaccumulation potential of substances in aquatic environments, which will help to ensure compliance with REACH regulations and minimize any risks associated with non-compliance.